Table 1.
Shedding of EBV from the oropharynx in patients receiving rituximab in the first study.
| Patient no. | Diagnosis | Treatment | Week of RTX therapy | EBV copies/106 PBMC* | EBV copies/106 throat wash cells |
|---|---|---|---|---|---|
| 1 | DLBCL | EPOCH-R | Pre | <100 | |
| 3 | 0 | ||||
| 4 | 0 | ||||
| 6 | <90 | 0 | |||
| 2 | Burkitt | EPOCH-R | Pre | 520 | |
| lymphoma | |||||
| 9 | 34,300,000 | ||||
| 12 | <40 | 34,300,000 | |||
| 14 | <140 | 172,000,000 | |||
| 3 | B cell | EPOCH-R | Pre | <160 | |
| lymphoma | 0 | ||||
| 1 | 0 | ||||
| 4 | 0 | ||||
| 4 | DLBCL | EPOCH-R | Pre | 93,000 | |
| 3 | <400 | 31,000,000 | |||
| 4 | <430 | ||||
| 5 | DLBCL | EPOCH-R | 5 | 672,000,000 | |
| HIV | 6 | <300 |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; EPOCH-R, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab; HIV, human immunodeficiency virus
*
Values with a “less than” sign were undetectable. The detection limit varied with the patient’s total white blood cell count on that day.